Post-marketing safety monitoring and study of Huachansu tablets after marketing

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300073452

Enrollment

Unknown

Registered

2023-07-11

Start date

2021-11-01

Completion date

Unknown

Last updated

2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Case series:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who take at least 1 time of Huachansu tablets in the inpatient department of the research institutes.

Exclusion criteria

Exclusion criteria: If the adverse reactions / events of a case maybe caused by other reasons, the experts groups need to discuss exclude the case or not.

Design outcomes

Primary

Measure	Time frame
Adverse reaction;The incidate rate of ADR/AE;	—

Countries

China

Contacts

Public ContactDong Liu

Baoji Central Hospital

pde@gdyl.org+86 138 2449 2310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026